Background-A national survey of tuberculosis was conducted in England and Wales in 1998 to obtain detailed information on the occurrence of the disease and recent trends. This survey also piloted the methodology for enhanced tuberculosis surveillance in England and Wales and investigated the prevalence of HIV infection in adults with tuberculosis. Methods-Clinical and demographic data for all cases diagnosed during 1998 were obtained, together with microbiological data where available. Annual incidence rates in the population were estimated by age, sex, ethnic group, and geographical region using denominators from the 1998 Labour Force Survey. Incidence rates in diVerent subgroups of the population were compared with the rates observed in previous surveys. The tuberculosis survey database for 1998 was matched against the Communicable Disease Surveillance Centre HIV/AIDS database to estimate the prevalence of HIV co-infection in adult patients with tuberculosis. Results-A total of 5658 patients with tuberculosis were included in the survey in England and Wales (94% of all formally notified cases during the same period), giving an annual rate of 10.93 per 100 000 population (95% CI 10.87 to 10.99). This represented an increase of 11% in the number of cases since the survey in 1993 and 21% since 1988. In many regions case numbers have remained little changed since 1988, but in London an increase of 71% was observed. The number of children with tuberculosis has decreased by 10% since 1993. Annual rates of tuberculosis per 100 000 population have continued to decline among the white population (4.38) and those from the Indian subcontinent, although the rate for the latter has remained high at 121 per 100 000. Annual rates per 100 000 have increased in all other ethnic groups, especially among those of black African (210) and Chinese (77.3) origin. Over 50% of all patients were born outside the UK. Recent entrants to the UK had higher rates of the disease than those who had been in the country for more than 5 years or who had been born in the UK. An estimated 3.3% of all adults with tuberculosis were co-infected with HIV.
National surveys of tuberculosis have been carried out in England and Wales every 5 years since 1978. [1] [2] [3] [4] These surveys have generally collected clinical, microbiological, and demographic data on notified cases for the first 6 months of the year and, in some, more limited data (on a restricted age group) in the second 6 months. The surveys have supplemented information on the incidence of tuberculosis from notifications and laboratory reports, permitting analyses of the trends in incidence in population subgroups defined by ethnic group and country of birth. The detailed information on the epidemiology of tuberculosis provided by the surveys has underpinned decisions on national treatment, control and prevention guidelines. A final survey was carried out in 1998 with the additional objective of piloting the methodology for a new system of continuous enhanced tuberculosis surveillance.
Methods
The survey was carried out by the Public Health Laboratory Service in collaboration with the British Thoracic Society and the Department of Health. The methodology of the survey diVered from that used in previous Thorax 2001; 56:173-179 surveys in certain key ways-namely, data were collected on all patients identified in the calendar year 1998, whether or not notified, and a coordinator was nominated by each district health authority with responsibility for ensuring that completed survey forms were collected and forwarded to the survey team at the Communicable Disease Surveillance Centre (CDSC), London.
Microbiological information, including drug susceptibility, on isolates reported to Mycobnet (the UK Mycobacterial Resistance Network, a surveillance system for all culture confirmed cases of tuberculosis) was matched by name and date of birth with the tuberculosis survey database. This supplemented the information provided by clinicians.
Matching was carried out between the 1998 tuberculosis survey database and the CDSC HIV/AIDS database, using previously described methodology, 5 to estimate the extent of co-infection of tuberculosis and HIV in adults.
Population figures for England and Wales were obtained from the 1998 Labour Force Survey (winter quarter and 1998 local area database). Rates were not calculated for population subgroups of less than 10 000 as the relative standard errors would have been too large. 6 In earlier surveys most analyses were of new (previously untreated) cases. Analyses of trends from 1988-98 used data from the earlier survey databases held at CDSC. To permit comparison, data from earlier surveys were re-analysed to include all patients, whether or not previously treated. As the earlier surveys had collected patient information for only 6 months in some age groups, these data were multiplied by scaling factors (as published previously 4 ) to give annual estimates for comparison of trends. Numbers cited in this article for the 1988 and 1993 surveys are therefore the annual numbers.
The 1998 survey data were entered and held in Access 95 Version 7 software and exported to SPSS Version 10 (SPSS Inc, Chicago, Illinois) for analysis. Analysis of HIV prevalence was conducted using Access 95 Version 7.
Results
In all, 6032 cases of tuberculosis were formally notified during weeks 1-52 of 1998. A revised estimate (5876) of the total for the study period (1 January to 31 December 1998) was derived from figures provided by district coordinators which took into account local over-and undernotification. A total of 6400 survey forms was received, of which 343 were excluded on the basis of information on the form (230 patients received chemoprophylaxis only and 113 were diagnosed or notified outside the survey period). A further 399 were excluded after they were subsequently found not to have tuberculosis. Thus, 5658 patients were eligible for inclusion in the survey. This represented 94% of all those formally notified and 96% of the district coordinators' estimate.
A total of 3506 laboratory reports of tuberculosis isolates were reported to Mycobnet in 1998; 629 of these could not be matched with patients on the survey database. InsuYcient information was available at the time of the survey to determine their eligibility so they were excluded. A subsequent audit of Mycobnet reports for 1998 carried out in 2000 (PHLS, unpublished data) determined that half of those reports for which information could be obtained would not have been eligible for inclusion in the survey-for example, patients notified outside the survey period or not resident in England and Wales.
Four hundred and forty five patients (7.9%) had been previously treated and 98 (1.7%) were known to have been diagnosed post mortem. The overall annual rate of tuberculosis in England and Wales was 10.93 per 100 000 (95% CI 10.87 to 10.99).
AGE AND SEX
The greatest numbers of cases were reported in those aged 15-34 years, followed by the 35-54 and 55-74 age groups ( fig 1A) . More cases overall were reported in males in all age groups, except in children where similar numbers were reported in boys and girls ( fig 1A) . The number of male patients was equal to or greater than the number of females in all but the Indian subcontinent (ISC: India, Pakistan and Bangladesh) ethnic group in which there were more females (fig 1B-D) .
The lowest annual rates per 100 000 were seen in children (<15 years of age): males 3.5 (95% CI 3.4 to 3.6); females 3.7 (95% CI 3.6 to 3.7). In all the adult age groups males had higher rates than females ( fig 1A) . In males the annual rate per 100 000 generally increased with increasing age, peaking in the elderly (>74 years) at 24.5 (95% CI 23.7 to 25.3). In contrast, the annual rate in females was highest in the 15-34 year age group and did not increase in the elderly. These overall rates ( fig 1A) hide substantial diVerences in age specific rates in ethnic subgroups of the population (fig 1B-D) . ETHNIC 
GROUP
In 1998 38% of patients with tuberculosis were reported from the ISC ethnic group. The proportion of white patients was also 38%, and 13% of patients were of black African ethnic origin (table 1). As in previous surveys, the numbers of cases in both the black Caribbean and Chinese ethnic groups have remained small, 7 comprising 2.2% and 1.8% of all cases, respectively. The highest annual rate per 100 000 was observed in the black African ethnic group (over 200), and an increased rate since the last survey was seen in the Chinese ethnic group which was nearly three times higher than the rate for those of black Caribbean origin. Rates in the white ethnic group were low (less than 5), while rates in the ISC ethnic group have remained high (over 100).
Place of birth and year of entry to the UK Fifty six per cent of patients were born abroad compared with 45% in 1988 and 50% in 1993 (data not shown). Of those born in the UK, most (77%) were of white ethnic origin. Most of those born abroad were of ISC ethnic origin (56%). Of all patients with known year of entry, 60% had been in the UK for longer than 5 years; 57% of patients of black African ethnic origin born abroad (where year of entry was known) were recent entrants to the UK (during the 5 years before the survey), whereas only 32% of ISC patients were recent arrivals (table  2) .
For all ethnic groups except black Caribbean the rates of tuberculosis were highest in those born abroad who had recently entered the UK, about one third lower in those born abroad but who had been in the UK for more than 5 years, and lowest in those born in the UK. Patients of ISC ethnic origin had the highest rates of all those born in the UK. The proportion born abroad for whom year of entry was unknown ranged from 22% (in the ISC ethnic group) to 39% (white ethnic group); had these patients' year of entry been known, corresponding rates of disease may have been higher than stated in table 2.
Geographical distribution
Of all cases reported, 40% were from London. The annual rate per 100 000 in London (31.6 (95% CI 31.2 to 32.1)) was four times the rate for the rest of England and Wales (7.65 (95% CI 7.61 to 7.70)). Annual rates for the remaining regions ranged from 4.22 (95% CI 4.16 to 4.29) in the Eastern region to 11.9 (95% CI 11.7 to 12.0) in the West Midlands (table 3) . Ten of the 15 district health authorities with more than 100 cases and/or an annual rate of >25 per 100 000 were in London (table 3) .
TRENDS IN NUMBER OF CASES AND ANNUAL

RATES OF DISEASE, 1988-98
The total number of patients with tuberculosis in 1998 (5658) represents an increase of 11% since the last national survey in 1993 and 21% The rate in the black Caribbean ethnic group did not change substantially between 1988 and 1998. In the ISC population the rate declined slightly, although it was 30 times higher than the rate for the white ethnic group in 1998. During the same period the rate for patients from the black African ethnic group increased by about a factor of three. The decline in the rate in the ISC population and the rise in the rate in the black African ethnic group remained even after standardising to the 1988 population, taking into account age, place of birth, and year of first entry to the UK (data not shown). More detailed analysis of the contribution of diVerent demographic factors will be carried out separately.
Figure 1 Age and sex distribution of proportion of patients with tuberculosis and rate of disease in (A) all patients (n=5653), (B) patients from the Indian subcontinent (ISC, n=2137), (C) white patients (n=2106), and (D) black African patients (n=743
Decline in the rate in the white population in England, 1978-98 The annual rate of disease in the white ethnic group has continued to decline with each survey between 1978 and 1998 ( fig 2) . The general trend of increasing rate with age persisted in both male and female patients, and was more marked in males. In females the rate per 100 000 only rose above 5 for those aged 65 years and over while in males this rate was reached by 35 years of age, increasing by a factor of three for men over 65 years.
Geographical distribution
With the exception of London, little change in the number of patients with tuberculosis has been observed in the NHS regions of England and Wales over the last decade. In London 927 more patients (an increase of 71%) were reported in 1998 than in 1988, accounting for much of the total increase in the number of patients between the two surveys. The annual rate per 100 000 in London rose from 19.9 in 1988 to 31.6 in 1998. There were urban areas other than London such as Leicester and Blackburn where the annual rates of tuberculosis were in the range of 30-50 per 100 000. However, although the rate in Leicester was greater than that for London, it has declined since 1988 (data not shown). Most of the high incidence urban areas outside Greater London had lower rates of tuberculosis in 1998 than in 1993. 7 Only two showed substantial increases (Sandwell and Kirklees; data not shown).
SITE OF DISEASE
The site of disease was known for 5625 (99%) patients. The proportion of patients with pulmonary disease (with or without extrapulmonary tuberculosis) decreased from 67% in 1988 to 63% in 1993 and 62% in 1998. The proportion of patients with extrapulmonary disease alone increased to 38% from 33% in 1988 and 37% in 1993. Nine per cent of patients had both forms of disease (mediastinal glands and pleural eVusion were considered extrapulmonary tuberculosis). A smaller proportion of children (49% of 358) than adults (63% of 5262) presented with pulmonary tuberculosis, while extrapulmonary disease alone was more common in children (51% v 37%). The proportion of patients with pulmonary tuberculosis increased with increasing age, reaching 78% in patients aged over 74 years. Detailed results for site of disease will be reported separately.
DIAGNOSIS
A positive culture was reported on specimens from 60% of all patients (66% of those with pulmonary disease; 50% with extrapulmonary disease only) compared with 59% in 1988. The proportion with a positive culture was much lower in children (0-14 years) than in adults (22% v 62%). A smear positive result for sputum was obtained for 27% of all patients, or 43% of patients with pulmonary disease. In 1.6% of all cases (92/5658) the laboratory support for the diagnosis was based on histological examination alone, mostly in patients with extrapulmonary disease only.
DRUG RESISTANCE
Of the 3385 patients reported with a positive culture, 3052 were matched to the Mycobnet database and drug resistance data were available for isolates from 3046 of these. Isoniazid resistance was present in the isolates from 153 patients (5.0%) compared with 2.9% in 1988, while multidrug resistance (defined as resistance to isoniazid and rifampicin, with or without resistance to any other drug) was present in 21 (0.7%) compared with 0.6% in 1988. The number of patients known to have been previously treated declined from 474 (10.2%) in 1988 to 445 (7.9%) in 1998. Isolates from these patients had higher levels of both isoniazid resistance (9.5%) and multidrug resistance (4.1%).
ESTIMATE OF HIV CO-INFECTION
In 1998 113 (3.3%) adult patients (16-54 years) with tuberculosis were co-infected with HIV compared with 62 (2.2%) in 1993. In London the proportion was higher and had also increased (5.4% in 1998; 3.3% in 1993). Most co-infected patients were from the black African or white ethnic groups. Detailed results of the overlap between tuberculosis and HIV infection will be reported separately.
Discussion
The number of reported cases of tuberculosis in England and Wales increased by 21% in the 10 years between 1988 and 1998. The increase occurred primarily in London where the number of patients with tuberculosis rose by 71% over this period. In 1998 the rates of disease were highest in the black African ethnic group, remained high but were decreasing gradually in the ISC population, had increased in the Chinese ethnic group, and were very low and continuing to decline in the white population. More than half of all patients with tuberculosis were born outside the UK and the year of entry was known for more than 75% of these. As in previous surveys, rates of disease remained particularly high in those who had recently arrived (between 1994 and 1998) from parts of the world with a high prevalence of tuberculosis. The number of patients born in the UK has continued to decline; this was reflected by continued reductions in rates both in the white population and in those of ISC origin when standardised for age, place of birth, and year of entry. Although greater than in 1993, the proportion of adult patients with tuberculosis co-infected with HIV was low overall. 
Tuberculosis at the end of the 20th century in England and Wales
The methodology used in the 1998 survey diVered from previous surveys. A district coordinator was responsible for collecting survey forms in each district. Cases were ascertained throughout the year and all cases known to the district coordinators, whether formally notified or not, were eligible for inclusion in the survey. These diVerences may have contributed to higher ascertainment of cases compared with previous surveys. 8 The increase in the number of patients between the 1988 and 1998 surveys (21%), however, is comparable to the increase in formally notified cases (18%) for the same period. Although it is not possible to quantify the extent of increased ascertainment in the 1998 survey, its eVect is likely to have been at least partly counterbalanced by the exclusion of some formally notified patients for whom a survey form could not be obtained. This is strengthened by the fact that the number of survey forms obtained was very close to the best estimate of cases for 1998 provided by district coordinators.
In earlier surveys most analyses were of new (previously untreated) cases. As diYculties exist in distinguishing with certainty those who have not had prior treatment, in this survey (unless otherwise stated) all cases were analysed together, whether or not previously treated. For comparison, data from the 1988 and 1993 surveys were re-analysed to include all cases, regardless of prior treatment status. As these surveys collected data on all age groups for only 6 months, the data were multiplied by scaling factors to permit comparisons of annual figures. Numbers and rates in this paper may therefore be diVerent from those published previously.
As in previous surveys, [1] [2] [3] [4] some patients who were started on treatment and notified as having tuberculosis were not subsequently denotified when the diagnosis of a nontuberculosis disease was made. De-notification remains important, both for local purposes (contact tracing) as well as for local and national surveillance. 9 Mechanisms to facilitate reporting a change of diagnosis have been incorporated into enhanced tuberculosis surveillance.
In some developed countries the reversal of the decline in the number of reported patients with tuberculosis has been partly attributed to extra cases as a result of an increasing number of patients born in high prevalence countries, [10] [11] [12] [13] [14] the HIV epidemic, 11 15 poverty, 13 16 and an ageing population. 17 18 In Europe 11 of the 15 countries providing information to the EuroTB scheme in 1997 reported that 35% of their foreign born tuberculosis patients were born in Africa. 19 Much of the increase in tuberculosis in England and Wales in the last 10 years was due to an increase in the number of patients who had been born abroad. Recent trends in migration into the UK may have contributed to the increased number of cases among new immigrants. The population of the black African ethnic group approximately trebled from 1988 to 1998, while the ISC population increased by about one third with most of this increase occurring between 1988 and 1993. The populations of white, black Caribbean, and Chinese ethnic groups in England and Wales have increased by less than 6% over the same period (Labour Force Survey population data from 1988, 1993 and 1998).
The geographical pattern of tuberculosis in England and Wales reflects the distribution of some high risk population subgroups. The large number of immigrants, especially recent immigrants, in London has contributed to the substantial increases observed in the capital. In addition, the tuberculosis/HIV co-infection rate increased in the 1990s in London (PHLS CDSC, personal communication). 15 Although the number of adult patients with tuberculosis infected with HIV in England and Wales nearly doubled between 1993 and 1998, this represented only 9% of the national increase in tuberculosis during this period. As information on the socioeconomic status of patients was not collected in this survey, no light can be shed on the eVect of poverty on the occurrence of tuberculosis. Further investigation of this issue would be possible using postcodes and indices of deprivation. Despite higher rates of tuberculosis in older people, and an ageing population in Britain, the increase in patients over 65 years of age accounted for less than 10% of the increase in England and Wales since 1988 (data not shown).
As in earlier national surveys, 3 4 most disease in 1998 was pulmonary in origin although the proportion of patients with a positive sputum smear in 1998 (27%) was lower than in 1993 (35%). Patients in the white ethnic group continued to contribute the largest proportion (54%) of potentially infectious cases (sputum smear positive) in the community. Prompt treatment of such patients, as well as identification and screening of their contacts, must remain an integral part of tuberculosis control to reduce transmission of infection in England and Wales.
If resources to control tuberculosis in England and Wales are to be used eYciently, they must be focused on the groups at highest risk of the disease such as new entrants to Britain from countries with a high prevalence of tuberculosis. Screening of new immigrants has been found to identify cases of active tuberculosis 20 21 but the current system is weak. 10 20 Strategies need to be devised to prevent the occurrence of disease in new immigrants more eVectively, and research needs to be carried out to determine the factors underlying the very high rates in new immigrants and the eVectiveness of intervention measures for this group. Not only should treatment services be capable of providing therapy for patients and prophylaxis for contacts, but they should also be provided in ways best suited to the needs of the population mix in the local community. This was the last in a series of five-yearly national tuberculosis surveys beginning in 1978, which have highlighted rapid changes in the epidemiology of tuberculosis in England and Wales. The implementation of continuous enhanced surveillance of all cases of tuberculosis from 1999 will provide a detailed and accu-rate picture of the occurrence of tuberculosis in a more timely way so that prevention and control measures can be adjusted to be more eVective, while making the most eYcient use of resources.
The authors would like to thank the clinicians, tuberculosis and chest clinic nurses, microbiologists and all other hospital or clinic staV who reported cases to the survey. We are grateful to all district coordinators and consultants in
We are indebted to the survey team, especially Francine Ryan, for invaluable work in data collection. Thanks are due to Peter Craig for programming and database advice. 
Case report
Method for manipulating peak flow measurements producing falsely raised readings S Ross, D P Cochran Abstract Methods by which patients can artificially produce raised peak flow measurements have been described. We recently observed a patient manipulating the peak flow meter in a way that had not been described before. A study was therefore undertaken to determine if this technique could repeatedly produce clinically significant changes in peak flow readings. Fifteen adults, using a mini-Wright peak flow meter, made five measurements using the correct technique followed by five manipulated measurements under observation. Significant increases in peak flow measurements were observed in 14 of the 15 subjects. The mean increase in peak flow rate using the incorrect technique was 56% (range -4% to 86%). Clinicians should be aware that patients might employ this technique to manipulate measurements which could have consequences for management. Peak flow measurement is used in asthma management. 1 We are aware that peak flow measurements can be artificially increased by spitting or coughing. 2 3 We recently observed a method of manipulating peak flow measurement which has not been previously described.
A 13 year old asthmatic boy was seen as an outpatient. He was prone to recurrent acute attacks of asthma and had four hospital admissions in the previous 3 months. The patient was asked to perform a peak flow measurement. During the manoeuvre his movements appeared slightly awkward and, when asked to explain, he admitted that he had discovered that, if he retarded the movement of the peak flow indicator with his index finger at the beginning of the manoeuvre for a fraction of a second after starting to exhale (fig 1) , he could increase the reading. He also explained that, if he moved vigorously during the procedure, it appeared that he was giving maximum eVort to performing the measurement and this made it diYcult for the doctor to detect what he was doing with his finger. A study was therefore undertaken to determine whether this technique could repeatedly produce clinically significant changes in peak flow readings.
Methods
Fifteen adults, one of whom had asthma, were asked to make five peak flow measurements in the standard way followed by a further five peak flow measurements by retarding the movement of the peak flow indicator as described in the case report, after an initial practice. All measurements were carried out using a mini-Wright peak flow meter.
Results
The results are shown in table 1. Both the mean and the best of five readings for the two techniques were recorded. It can be seen that altering the technique of peak flow measurement (as described in the case study) produced significant increases in peak flow rate in 14 of the 15 subjects. Using the mean of the five attempts, a mean increase of 28% (range -2% to 66%) was achieved. When the highest of the five attempts was taken as representative, the mean increase was 56% (range -4% to 85%).
Discussion
Peak flow recording is important in asthma management 1 and these measurements are used to inform decisions about the need for referral to hospital, admission, and timing of discharge. Patients dislike being in hospital and may be tempted to manipulate peak flow measurements in order to give falsely raised readings that could influence their management. For example, patients may have a true peak flow <50% of their personal best but, by falsely increasing the peak flow measurement by 28%, management could be quite diVerent. Clinicians need to be aware of this and of other manoeuvres that lead to falsely raised readings. We would emphasise that it is possible to interfere with the movement of the peak flow indicator with subtlety and this would not be readily noticed unless the clinician is watching closely. Asking patients to "cradle" the peak flow meter with a hand underneath the device is likely to prevent this problem. 
LETTERS TO THE EDITOR
CFC transition
Dr Everard wrote such a wide ranging polemic against inhaled therapy that it is difficult to know where to start. While the article contains a good deal of sense, it also contains a number of inaccuracies and misperceptions. I think the record needs to be put straight. Firstly, Dr Everard says that inhaled insulin will be in use in 2001. However, as far as I am aware, no application for delivery of insulin as an aerosol has yet been submitted to the FDA. New devices for the delivery of insulin are under trial, but the earliest they are likely to get to the market is 2002. They are likely to be relatively complex devices costing perhaps 100 times more than the current price for a salbutamol metered dose inhaler (MDI).
Secondly, Dr Everard berates the pharmaceutical industry for its eVorts in moving away from chlorofluorocarbon (CFC) MDIs. In 1996, when the Montreal protocol came into force, there was a real risk that MDIs for use in asthma/COPD would no longer be available. The industry started 10 years ago to try to reformulate MDIs but the technical challenge has been enormous and complicated by intellectual property issues. Only now, more than a decade later, are a suYcient number of CFC free MDIs coming to the market so that the transition can be completed over the next 2-4 years. This has cost a huge amount of money. But where is the evidence that they prevented new chemical entities for asthma coming to the market? If such clinically eYcacious compounds were available, then I am certain that they would have been commercially exploited.
Thirdly, Dr Everard is correct in stating that the MDI in some ways is a less than ideal inhalation device. The new hydrofluorocarbon (HFC) beclomethasone product (Qvar, 3M Pharmaceuticals) has a much smaller particle size, not by design but by necessity. This results in something like 5-6 times more drug being deposited peripherally in the lung but only twice the therapeutic eVect compared with the MDI it replaces. This product has given a big "wake up call" to the industry and we should all be asking which particle size really is ideal, particularly for inhaled steroids. Is it diVerent, for example, for beclomethasone versus budesonide versus fluticasone? I am also unaware of any data that monodispersed aerosols are more eYcacious or safer than aerosols with a more broad range of particle size.
Fourthly, Dr Everard mixes in with the discussion of technology a rather paternalistic view of patient compliance. If only patients would do as they are told and take their medication all would be well. Does anyone ever complete a course of antibiotics? We badly need more information about why patients do not adhere to medication regimes and what information they need about their disease and the treatments used. But isn't this true for all therapies? Dose counters to improve compliance might be valuable for MDIs-but where is the evidence that they are cost eVective, or even that doctors or patients want them?
I am firmly convinced that the MDI, along with the dry powder inhaler (DPI), is here to stay. They are remarkably cheap, instantly eVective as bronchodilators, and have an excellent therapeutic ratio for inhaled steroids for most asthmatics. Many patients can use up to 2000 doses per year without their inhaler letting them down, and perhaps it is not surprising that they become reliant on them. Certainly they can be improved upon. Novel devices using aqueous and hydrocarbon propellants are on their way. But if Dr Everard sees any viable and cost eVective alternatives, then let us hear about them. Mark Everard's superb leading article 1 railing against the numerous inadequacies of inhaled therapy delivered by pMDIs is to be applauded, but ultimately is an unsatisfying tract since it does not point to any solutions applicable in the here and now. The single most important advance in the treatment of asthma at the beginning of the 21st century would be to wean ourselves-and by that I mean the UK since the process is already well advanced in continental Europe-from the use of these archaic impediments to treatment. Everard is right that the regulatory authorities bear a heavy burden of guilt by requiring devices which result in greater lung deposition to undergo much more extensive, and therefore costly, investigation than "me too" devices mimicking the appalling performance of pMDIs. I have witnessed the "detuning" of novel inhalers that he refers to in order to limbo under this bureaucratic hurdle. Removing the equivalence straight jacket for inhaler devices would, at a stroke, allow currently available devices to be used to their maximum and not minimum potential.
Why are the British so hooked on the inadequate and obsolete pMDI? It is simply that Thorax 2001;56:501-504 the currently available alternative-dry powder inhalers-are perceived to be more costly. This view has been led by the Department of Health who have calculated that swapping device for device would cost them a great deal of money. This, however, is the accountancy of the madhouse. Because dry powder inhalers are more eYcient at drug delivery, the Fairy Liquid argument holds and the cost of treatment rather than the cost of the device should be used in their calculations. Of course, such back of the cigarette packet arithmetic should be banished by the new god of evidence based medicine. So what is the evidence on cost? Howarth et al have performed an audit of patients who have been transferred to dry powder inhalers because they were unable to use pMDIs. 2 The cost of treatment with inhaled steroids was actually lower with dry powder inhalers. The only randomised controlled trial using the overpriced Turbohaler came to a similar conclusion. 3 Thus, what little evidence that is available suggests that prescribing even premium priced dry powder inhalers for the delivery of inhaled steroids may be cheaper than using pMDIs. There can be no argument that there is a cost impediment with the more recent introduction of generic dry powder inhalers which are competitive even on a device for device basis.
Everard rightly points out that the issues of compliance, competence, and contrivance are closely interlinked. What is rarely taken into account in the equation is the patient preference. We have recently analysed the results of three separate studies comparing the market leading pMDI with the Clickhaler in terms of patient preference in 118 paediatric and 221 adult patients. 4 Significantly more (63%) preferred the dry powder inhaler to the pMDI (28%) (p<0.01). The dry powder inhaler was also significantly better on other criteria such as ease of use and ease of preparation. Similar results have been obtained in a meta-analysis of comparative studies of 802 patients using the dry powder device Easyhaler. 5 If patient preference is a surrogate for compliance, then two of Everard's three Cs can be dealt with today by transferring patients not optimally managed on pMDIs to dry powder devices.
The third C-contrivance-will be tackled shortly with the advent of new chip technologies already available in nebulised devices such as the Halolite Adaptive Aerosol Delivery (AAD) system. In Hull, Kastelik and Aziz have recorded patient compliance in 23 subjects using the AAD system and have unsurprisingly found that 20% of patients were poor compliers (<70% of doses). We have been unable to detect this lack of compliance during a formal structured interview or on diary record cards. In future the identification of such problems with smaller devices attached to inhalers will not only be of great medical benefit but also, I suspect, will be led by cost. Vast sums of money are wasted in health care by poor adherence to treatment. Woodcock appears to have misunderstood the purpose of the article when he characterises it as "polemic against inhaled therapy". The article was written precisely because I do recognise the importance of inhaled therapy and, in particular, the importance of inhaled corticosteroids for the treatment of asthma. Since aerosol therapy is so important, it should be clear that patients deserve to be provided with devices that deliver the drugs reliably and safely to the lungs. More than a decade ago pharmaceutical companies understandably decided to develop CFC replacement pMDIs. This was not because this was the best solution for patients but because at the time it appeared to be the quickest and cheapest solution. Much to their dismay, they found that this has proved to be a very expensive and long winded exercise. It is, however, important to recognise that the major error in judgement at that time was not that they underestimated the diYculties involved, but the failure to recognise the limitations of the pMDI as a delivery system for drugs other than short acting agonists. The pMDI was a brilliant solution for a particular problem but does not eVectively meet the needs of drugs such as inhaled corticosteroids. The challenges for device developers are, firstly, that they must develop a device that can deliver drug eVectively to the lungs and, secondly, to produce devices that all patients can and will use eVectively. The pMDI and many other technologies can generate aerosols that will deliver drug to the lungs but there has been little eVort to meet the second objective. pMDIs are simple to use but very diYcult to use eVectively. It is inevitable that novel devices will come to the market in coming years, not least because of expiry of drug patents. However, to ensure that all patients derive maximum benefit from this form of therapy in the future it is important to understand the limitation of current delivery systems and to place patient issues squarely at the forefront of future developments. There is now a vast range of novel and impressive technologies available, but unfortunately aerosol scientists appear all too often to be caught up in this exciting technology, forgetting that devices are only there to serve the consumer. The technology is not an end in itself but a means to an end.
The article deliberately avoided proposing specific solutions as the pharmaceutical companies do face many challenges. A major problem is that we do not have a simple method of assessing the "therapeutic index" of a given device so it is very diYcult to determine whether a novel device and/or drug is "as safe" as others on the market; the principle of using the "lowest eVective dose" therefore remains the best guide. Consideration of the issues of compliance, competence and contrivance are, however, essential if future devices are to meet the needs of patients. The studies Professor Morice cites are certainly a move in the right direction since they attempt to address the relative benefits of drug/device combinations in the real world.
Professor Woodcock was indeed correct to note that it will be at least a year before inhaled insulin is used in clinical practice. This error was noted soon after the article went to press and a correction to this eVect appeared on the Thorax website before the article appeared in print and on page 978 of the November 2000 issue of Thorax. 1 He is, however, incorrect in both his estimation of the complexity of the device and of its likely price; any increase in cost will not be attributable to the production of the device but the premium charged for a novel form of treatment. The issue was raised to illustrate the point that simple to use, eVective devices can be developed to serve specific functions.
My views on compliance are far from paternalistic. As noted in the article, noncompliance is common in all diseases and the factors contributing to it are complex. There are no easy solutions for an issue that is responsible for excess morbidity, mortality, and healthcare costs. However, modern technology can certainly impinge on this area since, as Professor Morice notes, it is possible not only to monitor whether a device is used but also to monitor whether the device is used correctly. Monitoring compliance is likely to be introduced in North America if managed care organisations find that they can reduce costs. I do not know if patients or doctors want such facilities in their delivery systems, but since it is now possible to monitor compliance in this way, a grown up, informed debate should be initiated. Certainly, objective compliance data can significantly improve the quality of a consultation by allowing the patient and professional to concentrate on the factors adversely aVecting compliance in an open and honest dialogue.
It is to be hoped that in the future novel devices will use appropriate technology to meet the needs of the patient rather than developing devices that force patients to adapt to the technology. 
M L EVERARD
Time to consign cromoglycate to history?
Sodium cromoglycate (SCG) has become a minority option for the treatment of childhood asthma, 1 and even positive trials show only marginally relevant diVerences in the outcomes measured. 2 It is therefore interesting to recall that in 1967 the majority of asthmatic subjects were exposed to cigarette smoke and many had deformed chests. Children were not allowed to self-medicate or to receive their treatment at ordinary schools; the most aVected were sent to special schools and camps. Oral ephedrine and short acting theophylline preparations were standard treatment, but their eVectiveness was limited by tachyphylaxis.
The children who were treated with SCG when it was introduced experienced less the currently available alternative-dry powder inhalers-are perceived to be more costly. exercise induced asthma and were able to participate in playground games, often for the first time. In addition, fewer colds resulted in wheezing and exacerbations were shorter. The parents and physicians of these children were delighted with this safe remedy which was eVective for all but the most severe forms of the condition. The most popular formulation was a mixture of SCG with isoprenaline (Intal compound). This combined the immediate bronchodilator eVect of a rapidly acting adrenergic drug of extremely short duration with protection from antigen challenges and exercise induced asthma which lasted for about 6 hours.
Salbutamol was introduced in 1969, only 2 years after SCG, and had the same eVect in providing both relief and protection. As soon as salbutamol, permitted 6-hourly, became the rescue bronchodilator of choice, it became diYcult to demonstrate any clinically relevant benefit attributable solely to SCG in patients who were not dependent on oral steroids. Inhaled beclomethasone was introduced soon afterwards and this enabled even more asthmatics who were dependent on oral steroids to discontinue them. Beclomethasone does not have the unpleasant taste that makes SCG disagreeable to use, and suppresses more components of inflammation than SCG. Furthermore, beclomethasone rapidly reduces symptoms more eVectively for the same eVect on daytime FEV 1 and morning peak flow, possibly by reducing the sensation of inflammation in the airways. 3 By the time it was recognised that long term administration of higher doses of inhaled steroids produced significant side eVects in children and adults, long acting bronchodilators had been developed and proved to be useful in combination with medium doses of inhaled steroids. The possible use of cromoglycate, with its proven safety record, was not investigated in this context. There are no long term studies which show whether SCG played any part in the improved outcomes in childhood asthma between 1970 and 1980, or whether these are entirely the consequence of inhaled steroid use.
In a lucid contemporary account, one of the first investigators to test SCG described how he and his colleagues were disappointed to be unable to show any major eVect of SCG on FEV 1 in spite of a dramatic symptomatic and steroid sparing eVect. 4 At this time asthma was defined as variable or reversible airflow obstruction, and it was recognised that patients would judge the control of their condition by the frequency of regular, unexpected, or nocturnal attacks rather than by their best lung function. The value of frequent observation during the day was demonstrated by Chai et al 5 in 1968 and accepted in the late 1970s even by physicians who had previously regarded paroxysmal nocturnal dyspnoea as synonymous with pulmonary oedema. Helms 1 points out that regulators and authors of meta-analyses have a duty to examine appropriate outcomes. To promote informed discussion, they also need to be aware of the changing therapeutic options that were available when the studies under scrutiny were carried out. AUTHORS' REPLY Lazlo provides an historical perspective on the passing cromoglycate era in which he describes the dire state of asthma management, particularly in children, at the time that sodium cromoglycate (SCG) was introduced. He also points out that, soon after SCG was introduced, inhaled isoprenaline became available followed by the selective 2 agonist salbutamol. Although isoprenaline in combination with SCG was common in adult practice, it was used much less frequently in children. There are a number of other child/adult diVerences in practice and eVectiveness that underline the insecurities of extrapolation and inference. 1 The protective eVects of cromones on exercise induced bronchoconstriction are established, but are of relatively short duration 2 and are therefore unlikely to provide reliable and sustained protection against this troublesome symptom in active children. Whereas long acting agonists have proved to be useful in combination with moderate doses of inhaled steroids in adults, 3 the eVects in young children have been disappointing 4 and have been the subject of a narrative review. 5 Extrapolation of experience from predominantly adult studies into the paediatric age range has been a feature of asthma management but is increasingly being shown to be insecure, again emphasising the need for studies in children, particularly in those in younger age groups where the disease is most prevalent.
1 There is at least one long term study which attempted to assess the eVectiveness of SCG and which concluded that 60-70% of children with persistent symptoms improved over a 3-5 year period. 6 However, this study, which was an open extension to a formal double blind placebo controlled trial, could not take into account the natural rates of resolution and recurrence of the disease over this prolonged period. 7 Despite the popularity of SCG in the 1970s and early 1980s, it could be argued that its marginal eVectiveness, masked by its combined use with eVective bronchodilator agents, together with concerns about possible systemic eVects of steroids prolonged its appearance in the therapeutic armamentarium. The passing cromoglycate era certainly contains many lessons for the prescribing community, and among these must be an awareness of the natural history of the disease in childhood and the potential pitfalls of extrapolating lessons learnt in more severely aVected and older age groups into younger age groups.
